NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free ACXP Stock Alerts $2.00 -0.03 (-1.48%) (As of 03:34 PM ET) Add Compare Share Share Today's Range$1.96▼$2.1350-Day Range$1.64▼$3.2552-Week Range$1.17▼$8.82Volume82,380 shsAverage Volume156,822 shsMarket Capitalization$31.52 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Acurx Pharmaceuticals alerts: Email Address Acurx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside503.0% Upside$12.00 Price TargetShort InterestBearish4.80% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.97) to ($2.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.02 out of 5 starsMedical Sector731st out of 907 stocksPharmaceutical Preparations Industry338th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.80% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently increased by 71.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Acurx Pharmaceuticals this week, compared to 1 article on an average week.Search Interest7 people have searched for ACXP on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.53% of the stock of Acurx Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to decrease in the coming year, from ($0.97) to ($2.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 5.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Acurx Pharmaceuticals Stock (NASDAQ:ACXP)Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Read More ACXP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACXP Stock News HeadlinesApril 25, 2024 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific ConferenceApril 23, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business UpdateApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 17, 2024 | nasdaq.comAcurx Pharmaceuticals Rings the Closing BellMarch 20, 2024 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | markets.businessinsider.comAcurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic PartnershipsMarch 19, 2024 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | finance.yahoo.comQ4 2023 Acurx Pharmaceuticals Inc Earnings CallApril 25, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 18, 2024 | investorplace.comACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023March 18, 2024 | finance.yahoo.comWe Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth CarefullyMarch 18, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateMarch 4, 2024 | prnewswire.comAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business UpdateFebruary 27, 2024 | finance.yahoo.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 27, 2024 | prnewswire.comAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU DevelopmentFebruary 17, 2024 | finance.yahoo.comACXP Mar 2024 4.000 callFebruary 16, 2024 | finance.yahoo.comACXP Mar 2024 5.000 putFebruary 2, 2024 | finance.yahoo.comNew to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PTFebruary 1, 2024 | finance.yahoo.comNew to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PTJanuary 26, 2024 | finance.yahoo.comNew to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PTJanuary 23, 2024 | finance.yahoo.comAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024January 17, 2024 | msn.comAcurx stock plunges 26% amid Phase 2 data release for C. diff drugJanuary 17, 2024 | msn.comELAB, KIND and RLX among pre-market losersJanuary 17, 2024 | markets.businessinsider.comAcurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b TrialJanuary 5, 2024 | finance.yahoo.comNew to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PTJanuary 3, 2024 | finance.yahoo.comAcurx to present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 28, 2023 | benzinga.comAcurx Pharmaceuticals Stock (NASDAQ:ACXP), Guidance and ForecastSee More Headlines Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today4/25/2024Next Earnings (Confirmed)5/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+503.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-289.69% Return on Assets-185.19% Debt Debt-to-Equity RatioN/A Current Ratio2.53 Quick Ratio2.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book5.85Miscellaneous Outstanding Shares15,760,000Free Float10,195,000Market Cap$31.36 million OptionableOptionable Beta-1.90 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Robert J. DeLuccia (Age 78)Co-Founder & Executive Chairman Comp: $701.54kMr. David P. Luci CPA (Age 57)Esq., J.D., Co-Founder, President, CEO & Director Comp: $668.98kMr. Robert G. Shawah CPA (Age 57)CPA, Co-Founder & CFO Comp: $470.29kKey CompetitorsImmunoPrecise AntibodiesNASDAQ:IPATheratechnologiesNASDAQ:THTXCASI PharmaceuticalsNASDAQ:CASIVYNE TherapeuticsNASDAQ:VYNEViracta TherapeuticsNASDAQ:VIRXView All CompetitorsInstitutional OwnershipProspect Financial Services LLCBought 17,700 shares on 4/23/2024Ownership: 1.732%NBC Securities Inc.Bought 14,000 shares on 4/5/2024Ownership: 0.089%Prospect Financial Services LLCBought 255,150 shares on 2/20/2024Ownership: 1.853%Sigma Planning CorpBought 10,000 shares on 2/1/2024Ownership: 0.073%View All Institutional Transactions ACXP Stock Analysis - Frequently Asked Questions Should I buy or sell Acurx Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACXP shares. View ACXP analyst ratings or view top-rated stocks. What is Acurx Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for Acurx Pharmaceuticals' stock. Their ACXP share price targets range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 503.0% from the stock's current price. View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts. How have ACXP shares performed in 2024? Acurx Pharmaceuticals' stock was trading at $3.83 at the start of the year. Since then, ACXP stock has decreased by 48.0% and is now trading at $1.99. View the best growth stocks for 2024 here. Are investors shorting Acurx Pharmaceuticals? Acurx Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 579,100 shares, an increase of 71.6% from the March 31st total of 337,400 shares. Based on an average daily trading volume, of 103,300 shares, the short-interest ratio is presently 5.6 days. Currently, 4.8% of the company's shares are sold short. View Acurx Pharmaceuticals' Short Interest. When is Acurx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 15th 2024. View our ACXP earnings forecast. How can I listen to Acurx Pharmaceuticals' earnings call? Acurx Pharmaceuticals will be holding an earnings conference call on Wednesday, May 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) posted its quarterly earnings data on Friday, March, 15th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.12. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an initial public offering (IPO) on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. Who are Acurx Pharmaceuticals' major shareholders? Acurx Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Prospect Financial Services LLC (1.73%) and NBC Securities Inc. (0.09%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACXP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsThe AI stock to buy right nowStockEarningsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
